
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 13)*

ImmunityBio, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

Charles Kenworthy
Cambridge Equities, LP, 450 Duley Road
El Segundo, CA, 90245
(310) 836-6400

Martin J. Waters
Wilson Sonsini Goodrich & Rosati, 12235 El Camino Real
San Diego, CA, 92130
(858) 350-2300

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/31/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1	Name of reporting person
	Cambridge Equities, LP
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a) ☒ (b)
3	SEC use only
4	Source of funds (See Instructions)
	AF, WC, OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	☐
6	Citizenship or place of organization
	DELAWARE
	Sole Voting Power
7	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
8	261,705,814.00
	Sole Dispositive Power
9	0.00
	Shared Dispositive Power
10	261,705,814.00
	Aggregate amount beneficially owned by each reporting person
11	261,705,814.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	☐
13	Percent of class represented by amount in Row (11)
	24.7 %
14	Type of Reporting Person (See Instructions)
	PN
Comment for Type of Reporting Person:	The percentage shown in (13) is calculated based upon (x) 261,705,814 shares of the Issuer's Common Stock held by Cambridge Equities, LP ("Cambridge"), divided by (y) 1,059,836,273 shares of the Issuer's Common Stock issued and outstanding, as of July 31, 2026 as provided by the Issuer.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person
	MP 13 Ventures, LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a) ☒ (b)
3	SEC use only
4	Source of funds (See Instructions)

	AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	☐
6	Citizenship or place of organization
	DELAWARE
	Sole Voting Power
7	0.00
Number of Shares Beneficially Owned by Each Reporting Person	Shared Voting Power
8	261,705,814.00
	Sole Dispositive Power
9	0.00
With:	Shared Dispositive Power
10	261,705,814.00
11	Aggregate amount beneficially owned by each reporting person
	261,705,814.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	☐
13	Percent of class represented by amount in Row (11)
	24.7 %
14	Type of Reporting Person (See Instructions)
	OO

Comment for Type of Reporting Person: The percentage shown in (13) is calculated based upon (x) 261,705,814 shares of the Issuer's Common Stock held by Cambridge, divided by (y) 1,059,836,273 shares of the Issuer's Common Stock issued and outstanding, as of July 31, 2026, as provided by the Issuer. MP 13 Ventures, LLC ("MP 13 Ventures") may be deemed to beneficially own, and share voting power and investment power with Cambridge over, all shares of the Issuer's Common Stock beneficially owned by Cambridge.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person
	NantWorks, LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☒ (b)
3	SEC use only
4	Source of funds (See Instructions)
	OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	☐
6	Citizenship or place of organization
	DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power
	0.00	
		Shared Voting Power
	8	
	98,535,253.00	
		Sole Dispositive Power
	9	
	0.00	
		Shared Dispositive Power
	10	
	98,535,253.00	
		Aggregate amount beneficially owned by each reporting person
	11	
	98,535,253.00	
		Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	12	
		☐
		Percent of class represented by amount in Row (11)
	13	
	9.3 %	
		Type of Reporting Person (See Instructions)
	14	
		OO

Comment for Type of Reporting Person: The percentage shown in (13) is calculated based upon (x) the sum of (i) 9,986,920 shares of the Issuer's Common Stock held by NantWorks, LLC ("NantWorks"); (ii) 8,383,414 shares of the Issuer's Common Stock held by NantBio, Inc. ("NantBio"); (iii) 47,557,934 shares of the Issuer's Common Stock held by NantMobile, LLC ("NantMobile"); and (iv) 32,606,985 shares of the Issuer's Common Stock held by NantCancerStemCell, LLC ("NCSC") divided by (y) 1,059,836,273 shares of the Issuer's Common Stock issued and outstanding, as of July 31, 2026, as provided by the Issuer. NantBio, NantMobile and NCSC are majority-owned subsidiaries of NantWorks, and NantWorks shares voting and dispositive power over the shares beneficially owned by NantBio, NantMobile, and NCSC. NantWorks disclaims beneficial ownership of the shares of the Issuer's Common Stock beneficially owned by NantBio, NantMobile and NCSC, except to the extent of their pecuniary interest.

SCHEDULE 13D

CUSIP No.

	Name of reporting person
1	Nant Capital, LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☐ (b)
3	SEC use only
	Source of funds (See Instructions)
4	OO
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	☐
	Citizenship or place of organization
6	DELAWARE

Number of Shares Beneficially Owned by Each	7	Sole Voting Power
	0.00	
	8	Shared Voting Power

Reporting Person With:	339,465,528.00
	Sole Dispositive Power
9	0.00
	Shared Dispositive Power
10	339,465,528.00
	Aggregate amount beneficially owned by each reporting person
11	339,465,528.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	☐
	Percent of class represented by amount in Row (11)
13	29.6 %
	Type of Reporting Person (See Instructions)
14	OO

Comment for Type of Reporting Person: The percentage shown in (13) is calculated based upon (x) the sum of (i) 251,018,873 shares of the Issuer's Common Stock held by Nant Capital, LLC ("Nant Capital"); and (ii) 88,446,655 shares of the Issuer's Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of July 31, 2026 pursuant to the conversion of a promissory note divided by (y) the sum of (i) 1,059,836,273 shares of the Issuer's Common Stock issued and outstanding, as of July 31, 2026, as provided by the Issuer; and (ii) 88,446,655 shares of the Issuer's Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of July 31, 2026 pursuant to the conversion of a promissory note.

SCHEDULE 13D

CUSIP No.

	Name of reporting person
1	California Capital Equity, LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☒ (b)
3	SEC use only
	Source of funds (See Instructions)
4	OO
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	☐
	Citizenship or place of organization
6	DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	Sole Voting Power
7	0.00
	Shared Voting Power
8	106,511,412.00
	Sole Dispositive Power
9	0.00
	10 Shared Dispositive Power

	106,511,412.00
11	Aggregate amount beneficially owned by each reporting person
	106,511,412.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	☐
13	Percent of class represented by amount in Row (11)
	10.0 %
14	Type of Reporting Person (See Instructions)
	OO

Comment for Type of Reporting Person: The percentage shown in (13) is calculated based upon (x) the sum of (i) 7,976,159 shares of the Issuer's Common Stock held by California Capital Equity, LLC ("California Capital"); (ii) 9,986,920 shares of the Issuer's Common Stock held by NantWorks; (iii) 8,383,414 shares of the Issuer's Common Stock held by NantBio; (iv) 47,557,934 shares of the Issuer's Common Stock held by NantMobile; and (v) 32,606,985 shares of the Issuer's Common Stock held by NCSC divided by (y) 1,059,836,273 shares of the Issuer's Common Stock issued and outstanding, as of July 31, 2026, as provided by the Issuer. NantWorks is a wholly-owned subsidiary of California Capital. NantBio, NantMobile and NCSC are majority-owned subsidiaries of NantWorks. California Capital shares voting and dispositive power over the shares beneficially owned by NantWorks, NantBio, NantMobile, and NCSC. California Capital disclaims beneficial ownership of the shares of the Issuer's Common Stock beneficially owned by NantWorks, NantBio, NantMobile and NCSC, except to the extent of their pecuniary interest.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person
	Patrick Soon-Shiong
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☐ (b)
3	SEC use only
4	Source of funds (See Instructions)
	AF, PF, OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	☐
6	Citizenship or place of organization
	UNITED STATES
	Sole Voting Power
7	32,217,205.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
8	713,301,080.00
	Sole Dispositive Power
9	32,217,205.00
	Shared Dispositive Power
10	713,301,080.00
11	Aggregate amount beneficially owned by each reporting person

745,518,285.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12



Percent of class represented by amount in Row (11)

13

64.8 %

Type of Reporting Person (See Instructions)

14

IN

Comment for Type of Reporting Person: The percentage in (13) is calculated based upon (x) the sum of (i) 29,757,911 shares of the Issuer's Common Stock held by Dr. Patrick Soon-Shiong; (ii) 2,459,294 shares of the Issuer's Common Stock that Dr. Soon-Shiong has the right to acquire from the Issuer within 60 days of July 31, 2026 pursuant to the exercise of stock options that were exercisable as of July 31, 2026; (iii) 261,705,814 shares of the Issuer's Common Stock held by Cambridge; (iv) 7,976,159 shares of the Issuer's Common Stock held by California Capital; (v) 9,986,920 shares of the Issuer's Common Stock held by NantWorks; (vi) 251,018,873 shares of the Issuer's Common Stock held by Nant Capital; (vii) 88,446,655 shares of the Issuer's Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of July 31, 2026 pursuant to the conversion of a promissory note; (viii) 8,383,414 shares of the Issuer's Common Stock held by NantBio; (ix) 47,557,934 shares of the Issuer's Common Stock held by NantMobile; (x) 32,606,985 shares of the Issuer's Common Stock held by NCSC; and (xi) 5,618,326 shares of the Issuer's Common Stock held by the Chan Soon-Shiong Family Foundation divided by (y) the sum of (i) 1,059,836,273 shares of the Issuer's Common Stock issued and outstanding, as of July 31, 2026, as provided by the Issuer; (ii) 2,459,294 shares of the Issuer's Common Stock that Dr. Soon-Shiong has the right to acquire from the Issuer within 60 days of July 31, 2026 pursuant to the exercise of stock options that were exercisable as of July 31, 2026; and (iii) 88,446,655 shares of the Issuer's Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of July 31, 2026, pursuant to the conversion of a promissory note. Dr. Soon-Shiong may be deemed to beneficially own, and share voting power and investment power over, all shares of the Issuer's Common Stock beneficially owned by Cambridge, California Capital, NantWorks, NantBio, NantMobile, NCSC, Nant Capital, and the Chan Soon-Shiong Family Foundation. Dr. Soon-Shiong disclaims beneficial ownership of the shares of the Issuer's Common Stock beneficially owned by Cambridge, California Capital, NantWorks, NantBio, NantMobile, NCSC, Nant Capital, and the Chan Soon-Shiong Family Foundation, except to the extent of his pecuniary interest.

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

(a)

Common Stock, par value \$0.0001 per share

Name of Issuer:

(b)

ImmunityBio, Inc.

Address of Issuer's Principal Executive Offices:

(c)

3530 John Hopkins Court, San Diego, CALIFORNIA , 92121.

Item 7. Material to be Filed as Exhibits.

The following documents are filed as exhibits: Exhibit 99.1 Joint Filing Agreement, dated as of September 21, 2023, by and among Cambridge Equities, LP, MP 13 Ventures, LLC, NantWorks, LLC, NantMobile, LLC, Nant Capital, LLC, California Capital Equity, LLC, and Patrick Soon-Shiong (incorporated by reference to Exhibit 99.1 to the Sch 13D/A (Amendment No. 9) filed with the SEC by the Reporting Persons on September 21, 2023). Exhibit 99.2 Nominating Agreement by and between the Issuer and Cambridge Equities, LP, dated June 18, 2015 (incorporated by reference to Exhibit 4.1 to the Issuer's Registration Statement on Form S-1 (File No. 333-205124) filed with the SEC on June 19, 2015). Registration Rights Agreement by and between the Issuer and Cambridge Equities, LP, dated December 23, 2014 (incorporated by reference to Exhibit 4.3 to the Issuer's Registration Statement on Form S-1 (File No. 333-205124) filed with the SEC on June 19, 2015).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Cambridge Equities, LP

Signature: /s/ Charles Kenworthy

Name/Title: Charles Kenworthy, Manager of MP 13 Ventures,
LLC, the General Partner of Cambridge Equities,
LP

Date: 08/06/2026

MP 13 Ventures, LLC

Signature: /s/ Charles Kenworthy

Name/Title: Charles Kenworthy, Manager

Date: 08/06/2026

NantWorks, LLC

Signature: /s/ Robert Morse

Name/Title: Robert Morse, CFO of NantWorks, LLC

Date: 08/06/2026

Nant Capital, LLC

Signature: /s/ Charles Kenworthy

Name/Title: Charles Kenworthy, Manager of Nant Capital,
LLC

Date: 08/06/2026

California Capital Equity, LLC

Signature: /s/ Charles Kenworthy

Name/Title: Charles Kenworthy, Manager of California
Capital Equity, LLC

Date: 08/06/2026

Patrick Soon-Shiong

Signature: /s/ Patrick Soon-Shiong

Name/Title: Patrick Soon-Shiong

Date: 08/06/2026